155 related articles for article (PubMed ID: 27628221)
1. Influence of Left Ventricular Ejection Fraction on the Effects of Supplemental Use of Angiotensin Receptor Blocker Olmesartan in Hypertensive Patients With Heart Failure.
Miura M; Sakata Y; Miyata S; Shiba N; Takahashi J; Nochioka K; Takada T; Saga C; Shinozaki T; Sugi M; Nakagawa M; Sekiguchi N; Komaru T; Kato A; Fukuchi M; Nozaki E; Hiramoto T; Inoue K; Goto T; Ohe M; Tamaki K; Ibayashi S; Ishide N; Maruyama Y; Tsuji I; Shimokawa H;
Circ J; 2016 Sep; 80(10):2155-64. PubMed ID: 27628221
[TBL] [Abstract][Full Text] [Related]
2. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial.
Sakata Y; Shiba N; Takahashi J; Miyata S; Nochioka K; Miura M; Takada T; Saga C; Shinozaki T; Sugi M; Nakagawa M; Sekiguchi N; Komaru T; Kato A; Fukuchi M; Nozaki E; Hiramoto T; Inoue K; Goto T; Ohe M; Tamaki K; Ibayashi S; Ishide N; Maruyama Y; Tsuji I; Shimokawa H; ;
Eur Heart J; 2015 Apr; 36(15):915-23. PubMed ID: 25637937
[TBL] [Abstract][Full Text] [Related]
3. Discharge treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction.
Vicent L; Cinca J; Vazquez-García R; Gonzalez-Juanatey JR; Rivera M; Segovia J; Pascual-Figal D; Bover R; Worner F; Delgado-Jiménez J; Fernández-Avilés F; Martínez-Sellés M
Intern Med J; 2019 Dec; 49(12):1505-1513. PubMed ID: 30887642
[TBL] [Abstract][Full Text] [Related]
4. Supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial--rationale and design.
Sakata Y; Nochioka K; Miura M; Takada T; Tadaki S; Miyata S; Shiba N; Shimokawa H
J Cardiol; 2013 Jul; 62(1):31-6. PubMed ID: 23769179
[TBL] [Abstract][Full Text] [Related]
5. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.
Lund LH; Claggett B; Liu J; Lam CS; Jhund PS; Rosano GM; Swedberg K; Yusuf S; Granger CB; Pfeffer MA; McMurray JJV; Solomon SD
Eur J Heart Fail; 2018 Aug; 20(8):1230-1239. PubMed ID: 29431256
[TBL] [Abstract][Full Text] [Related]
6. Effects of a changeover from other angiotensin II receptor blockers to olmesartan on left ventricular hypertrophy in heart failure patients.
Shimoura H; Tanaka H; Matsumoto K; Mochizuki Y; Hatani Y; Hatazawa K; Matsuzoe H; Ooka J; Sano H; Sawa T; Motoji Y; Ryo-Koriyama K; Hirata KI
Heart Vessels; 2017 May; 32(5):584-590. PubMed ID: 27722772
[TBL] [Abstract][Full Text] [Related]
7. Long-term prescription of beta-blocker delays the progression of heart failure with preserved ejection fraction in patients with hypertension: A retrospective observational cohort study.
Gu J; Fan YQ; Bian L; Zhang HL; Xu ZJ; Zhang Y; Chen QZ; Yin ZF; Xie YS; Wang CQ
Eur J Prev Cardiol; 2016 Sep; 23(13):1421-8. PubMed ID: 26915580
[TBL] [Abstract][Full Text] [Related]
8. Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure.
Wolsk E; Claggett B; Køber L; Pocock S; Yusuf S; Swedberg K; McMurray JJV; Granger CB; Pfeffer MA; Solomon SD
Eur J Heart Fail; 2018 Mar; 20(3):504-510. PubMed ID: 29193462
[TBL] [Abstract][Full Text] [Related]
9. Renin-Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction: A Meta-Analysis of Published Study Data.
Beldhuis IE; Streng KW; Ter Maaten JM; Voors AA; van der Meer P; Rossignol P; McMurray JJ; Damman K
Circ Heart Fail; 2017 Feb; 10(2):. PubMed ID: 28209765
[TBL] [Abstract][Full Text] [Related]
10. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme.
Damman K; Solomon SD; Pfeffer MA; Swedberg K; Yusuf S; Young JB; Rouleau JL; Granger CB; McMurray JJ
Eur J Heart Fail; 2016 Dec; 18(12):1508-1517. PubMed ID: 27427441
[TBL] [Abstract][Full Text] [Related]
11. Differential impact of heart rate and blood pressure on outcome in patients with heart failure with reduced versus preserved left ventricular ejection fraction.
Maeder MT; Kaye DM
Int J Cardiol; 2012 Mar; 155(2):249-56. PubMed ID: 21035207
[TBL] [Abstract][Full Text] [Related]
12. Heart Failure and Midrange Ejection Fraction: Implications of Recovered Ejection Fraction for Exercise Tolerance and Outcomes.
Nadruz W; West E; Santos M; Skali H; Groarke JD; Forman DE; Shah AM
Circ Heart Fail; 2016 Apr; 9(4):e002826. PubMed ID: 27009553
[TBL] [Abstract][Full Text] [Related]
13. Impact of elevated heart rate on clinical outcomes in patients with heart failure with reduced and preserved ejection fraction: a report from the CHART-2 Study.
Takada T; Sakata Y; Miyata S; Takahashi J; Nochioka K; Miura M; Tadaki S; Shimokawa H;
Eur J Heart Fail; 2014 Mar; 16(3):309-16. PubMed ID: 24464774
[TBL] [Abstract][Full Text] [Related]
14. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response.
Kao DP; Lewsey JD; Anand IS; Massie BM; Zile MR; Carson PE; McKelvie RS; Komajda M; McMurray JJ; Lindenfeld J
Eur J Heart Fail; 2015 Sep; 17(9):925-35. PubMed ID: 26250359
[TBL] [Abstract][Full Text] [Related]
15. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry.
Senni M; Gavazzi A; Oliva F; Mortara A; Urso R; Pozzoli M; Metra M; Lucci D; Gonzini L; Cirrincione V; Montagna L; Di Lenarda A; Maggioni AP; Tavazzi L;
Int J Cardiol; 2014 May; 173(2):163-9. PubMed ID: 24630337
[TBL] [Abstract][Full Text] [Related]
16. Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF: Insights From the CIBIS-ELD Trial.
Edelmann F; Musial-Bright L; Gelbrich G; Trippel T; Radenovic S; Wachter R; Inkrot S; Loncar G; Tahirovic E; Celic V; Veskovic J; Zdravkovic M; Lainscak M; Apostolović S; Neskovic AN; Pieske B; Düngen HD;
JACC Heart Fail; 2016 Feb; 4(2):140-149. PubMed ID: 26682793
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 5-Year Outcomes After Coronary Artery Bypass Grafting in Heart Failure Patients With Versus Without Preserved Left Ventricular Ejection Fraction (from the CREDO-Kyoto CABG Registry Cohort-2).
Marui A; Nishiwaki N; Komiya T; Hanyu M; Tanaka S; Kimura T; Sakata R;
Am J Cardiol; 2015 Aug; 116(4):580-6. PubMed ID: 26092271
[TBL] [Abstract][Full Text] [Related]
18. Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: A systematic review and network meta-analysis of randomized clinical trials.
Bao J; Kan R; Chen J; Xuan H; Wang C; Li D; Xu T
Pharmacol Res; 2021 Jul; 169():105573. PubMed ID: 33766629
[TBL] [Abstract][Full Text] [Related]
19. Natural history of left ventricular ejection fraction in patients with heart failure.
Clarke CL; Grunwald GK; Allen LA; Barón AE; Peterson PN; Brand DW; Magid DJ; Masoudi FA
Circ Cardiovasc Qual Outcomes; 2013 Nov; 6(6):680-6. PubMed ID: 24129973
[TBL] [Abstract][Full Text] [Related]
20. Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.
Verbrugge FH; Duchenne J; Bertrand PB; Dupont M; Tang WH; Mullens W
Am J Cardiol; 2013 Dec; 112(12):1913-20. PubMed ID: 24286620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]